IDO1 and glioblastoma: Other amino acid pathways are being evaluated in clinical trials, such as indoleamine-2,3-dioxygenase-1 (IDO1) inhibitors, epacadostat and indoximod, for tryptophan catabolism in cervical cancer and glioblastoma (143–145).